Description: Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Home Page: pharvaris.com
Emmy Noetherweg 2
Leiden,
2333 BK
Netherlands
Phone:
31 71 203 6410
Officers
| Name | Title |
|---|---|
| Mr. Berndt Axel Edvard Modig CPA, M.B.A. | Co-Founder, CEO & Executive Director |
| Ms. Anna Nijdam M.Sc., R.A. | Head of Strategic Finance & Principal Accounting Officer |
| Dr. Stefan Abele Ph.D. | Chief Technology Operations Officer |
| Ms. Annick Deschoolmeester | Chief Human Resources Officer |
| Dr. Peng Lu M.D., Ph.D. | Chief Medical Officer |
| Dr. Anne A. Lesage Ph.D. | Chief Early Development Officer |
| Mr. Wim Souverijns Ph.D. | Chief Commercial Officer |
| Mr. David W. Nassif J.D. | CFO & Corporate Secretary |
| Maryann Cimino | Director of Corporate Relations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.2892 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 83 |